Veru announces presentation of phase 3 study of sabizabulin for the treatment of hospitalized covid-19 patients at high risk for acute respiratory distress syndrome at the 11th international conference on emerging infectious diseases (iceid) on august 7-10, 2022

Miami, aug. 09, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced that the phase 3 covid-19 study results of sabizabulin for the treatment of hospitalized covid-19 patients at high risk for acute respiratory distress syndrome (ards) were presented at the 11th international conference on emerging infectious diseases (iceid) on august 8, 2022.
VERU Ratings Summary
VERU Quant Ranking